Systemic sclerosis & Raynaud's
Osteoporosis is associated with anti-topoisomerase I positivity and glucocorticoids use in patients with systemic sclerosis
Authors' conclusion
Our study shows that OP risk in patients with SSc is determined by age, disease-related factors such as diffuse cutaneous subset, ILD and anti-topoisomerase I antibody positivity, but also treatment with GC independently of other factors.
Study context
- Population
- Patients with systemic sclerosis (SSc) fulfilling the ACR/EULAR 2013 criteria, followed in the Lille University Hospital
- Participants
- 485 patients
- Outcome
- OP (T-score below −2.5 at femoral neck or lumbar spine, previous major osteoporotic fracture, or anti-osteoporotic therapy) and its risk factors
Methodological detailsbased on a large prospective cohort, retrospectively collected bone health data, univariable and multivariable analysis
- Based on a large prospective cohort
- Retrospectively collected bone health data
- Univariable and multivariable analysis
Main finding
As reported in the abstract
Factors independently associated with OP (multivariable analysis)
Odds ratio (95% CI)
Higher age
1.06(1.04–1.08)
Anti-topoisomerase I antibody positivity
2.22(1.18–4.16)
Treatment with GC
4.48(2.42–8.26)
- Prevalence of osteoporosis (OP)
- 23%
Observational data: associations, not effects.
Further findings
Fragility fractures
- Fragility fractures occurred in patients
- 18%
Factors associated with OP (univariable analysis)
- OP associated with higher age, diffuse cutaneous subset, interstitial lung disease (ILD), anti-topoisomerase I positivity, treatment with glucocorticoids (GC) and DMARDs
Original publication
Osteoporosis is associated with anti-topoisomerase I positivity and glucocorticoids use in patients with systemic sclerosis. Rheumatology (Oxford). Published 7 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →